Setmelanotide by Rhythm Pharmaceuticals
Overview: Setmelanotide is a drug developed by Rhythm Pharmaceuticals to address rare genetic disorders of obesity, including Bardet-Biedl Syndrome (BBS). It targets the melanocortin-4 receptor (MC4R) pathway, which is crucial in regulating hunger and energy expenditure. In certain genetic disorders, this pathway is disrupted, leading to severe obesity that typically begins in childhood.
How It Works: Setmelanotide acts as an MC4R agonist, meaning it activates this receptor to restore normal signaling related to hunger and energy balance in the brain. By doing so, it helps reduce excessive hunger (hyperphagia) and promotes weight loss in individuals with genetic mutations affecting this pathway.
Indications: Setmelanotide has been approved for use in treating specific genetic obesity disorders, including:
- Bardet-Biedl Syndrome (BBS)
- Proopiomelanocortin (POMC) deficiency
- Proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency
- Leptin receptor (LEPR) deficiency
Bardet-Biedl Syndrome, in particular, is characterized by a range of symptoms, including obesity, and setmelanotide offers a targeted approach to managing this aspect of the syndrome.
Clinical Impact: Clinical trials have demonstrated that setmelanotide can lead to significant weight loss and reduced hunger in individuals with BBS and other genetic conditions. By addressing the underlying cause of obesity in these patients, setmelanotide offers a treatment option that goes beyond managing symptoms.
Resources:
https://rhythmtx.com/overview/